Sun Pharma Secures Rs 828 Crore Refund as CESTAT Declares Revenue Department’s Demand as Legally Invalid

Delhi High Court grants interim relief to Sun Pharma in trademark dispute, restraining Alenvision from selling its NEXADOM medication amidst allegations of infringing on Sun Pharma’s NAXDOM trademark.

The Delhi High Court has granted interim relief to Sun Pharma in a trademark dispute over the name “NAXDOM”. The court has barred Alenvision from manufacturing and selling a drug called “NEXADOM”, which Sun Pharma claims is deceptively similar...